But less than one in five say they have personally benefited.

Fueled by strong demand because of its personalized testing providers, CSI Laboratories will use this new facility to achieve greater three-fold increase in laboratory capacity, medical offices, and administrative support. This new service expands our reach and we can become the testing partner of preference for pathologists and hospitals throughout the nation. Laboratory directors, Lawrence Hertzberg, M.D., Steve Kargas, M.D., Ph.D. And Theresa Brown, Ph.D., each still left Genzyme Genetics to join CSI over the past three years.CSI third quarter revenues increase 5 percent to $21.2 million Cardiovascular Systems, Inc. , a medical device company commercializing and developing innovative interventional treatment systems for vascular disease, reported financial results today because of its fiscal third quarter ended March 31, 2012. CSI’s revenues in the third quarter rose to $21.2 million, an 8 % increase over the second quarter of fiscal 2012, and a 5 % gain over revenues of $20.2 million in the third quarter of last fiscal year. Revenues from consumer reorders had been 96 % of total revenue, compared to 94 % a year ago.